US2008274129A1PendingUtilityA1
Hla-A2 Tumor Associated Antigen Peptides and Compositions
Est. expiryApr 18, 2023(expired)· nominal 20-yr term from priority
A61P 35/04A61P 35/00A61K 2039/55511A61K 2039/572C07K 7/06A61K 39/39A61K 2039/57A61K 2039/55566A61K 2039/70C07K 14/47A61K 40/4268A61K 40/4266A61K 40/4241A61K 40/4205A61K 40/24A61K 40/19A61K 2239/31A61K 39/0011
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
Claims
exact text as granted — not AI-modified1 - 14 . (canceled)
15 . A composition comprising at least three peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
16 . A composition according to claim 15 , further comprising a fourth peptide, wherein said fourth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
17 . A composition according to claim 16 , further comprising a fifth peptide, wherein said fifth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
18 . A composition according to claim 17 , further comprising a sixth peptide, wherein said sixth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
19 . A composition according to claim 18 , further comprising a seventh peptide, wherein said seventh peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
20 . A composition according to claim 19 , further comprising a eighth peptide, wherein said eighth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
21 . A composition according to claim 20 , further comprising a ninth peptide, wherein said ninth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
22 . A composition according to claim 15 , further comprising an additional peptide, wherein said additional peptide is less than 25 amino acid residues in length and comprises an helper T lymphocyte (HTL) epitope.
23 . A composition according to claim 22 , wherein said additional peptide is a PanDR binding peptide.
24 . A composition according to claim 23 , wherein said Pan DR binding peptide comprises the amino acid sequence aKXVAAWTLKAAa (SEQ ID NO:1).
25 . A composition according to claim 15 , further comprising a liposome.
26 . A composition according to claim 15 , further comprising a lipid.
27 . A composition according to claim 15 , further comprising an antigen presenting cell.
28 . A composition according to claim 27 , wherein said antigen presenting cell is a dendritic cell.
29 . A composition according to claim 15 , further comprising a pharmaceutical excipient.
30 . A composition according to claim 29 , wherein said pharmaceutical excipient is an adjuvant.
31 . A composition according to claim 30 , wherein said adjuvant is a mineral oil adjuvant.
32 . An isolated nucleic acid encoding at least three peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:
RLLQETELV,
(SEQ ID NO:2)
YLQLVFGIEV,
(SEQ ID NO:3)
LLTFWNPPV,
(SEQ ID NO:4)
SMPPPGTRV,
(SEQ ID NO:5)
KLBPVQLWV,
(SEQ ID NO:6)
KVFGSLAFV,
(SEQ ID NO:7)
YLSGADLNL,
(SEQ ID NO:8)
IMIGHLVGV,
(SEQ ID NO:9)
and
KVAEIVHFL.
(SEQ ID NO:10)
33 . A method for the treatment or prevention of cancer, said method comprising administering the composition of claim 15 to a patient in need thereof.
34 . A method according to claim 33 , wherein said treatment delays the recurrence of cancer following surgery, radiation therapy or chemotherapy.
35 . A method according to claim 33 , wherein said treatment prevents the metastasis of a primary tumor.
36 . A method according to claim 33 , wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.
37 . A method for the treatment or prevention of cancer, said method comprising administering the nucleic acid of claim 32 to a patient in need thereof.
38 . A method according to claim 37 , wherein said treatment delays the recurrence of cancer following surgery, chemotherapy or radiation.
39 . A method according to claim 37 , wherein said treatment prevents the metastasis of a primary tumor.
40 . A method according to claim 37 , wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.